Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EUTRON is an oral small-molecule tablet in pre-launch development by Abbott under NDA review. The mechanism of action, indications, and pharmacologic class remain undisclosed, limiting public assessment of its therapeutic positioning.
Pre-Launch
As a pre-launch asset, EUTRON will generate entry-level and mid-career roles in launch preparation, including brand strategy, training, and early sales infrastructure build.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies
Started Aug 2026
35 enrolled
Head and Neck Cancer
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors
Started Jun 2025
10 enrolled
Malignant Brain Tumors
Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers
Started May 2025
24 enrolled
Head and Neck CancerBoron Neutron Capture Therapy
Accelerator-based BNCT (Boron Neutron Capture Therapy) for Head and Neck Carcinoma.
Started May 2025
10 enrolled
Head and Neck Carcinoma
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
Started Oct 2024
10 enrolled
MeningiomaBoron Neutron Capture Therapy
Worked on EUTRON at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.